

Receivables 17681 23477 21276 27533 22365 34301 Other 69069 78437 85779 Current Assets 31958 Accts Payable 27715 34224 Debt Due 3110 58412 4274 62822 4545 Other 65000 89237 99054 Current Liab. 103769

Past Est'd '21-'23 ANNUAL RATES Past 10 Yrs. to '28-'30 of change (per sh) 5 Yrs. Revenues "Cash Flow" 12.5% 15.0% 10.5% 15.5% 8.5% 10.0% Earnings Dividends 16.5% 17.5% 15.5% **Book Value** 11.0% 12.5%

Cal- endar	QUAF Mar.31	RTERLY RI Jun.30	EVENUES Sep.30		Full Year
2022	80149	80332	80894	82787	324162
2023	91931	92903	92361	94427	371622
2024	99796	98855	100820	100807	400278
2025	111640	112460	113375	114875	452350
2026	120000	120750	121700	123150	485600
Cal-	EARNINGS PER SHAREA				Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2022	5.49	5.57	5.79	5.34	22.19
2023	6.26	6.14	6.56	6.16	25.12
2024	6.91	6.80	7.15	6.81	27.67
2025	7.30	7.50	7.75	7.25	29.80
2026	8.30	8.40	8.65	8.20	33.55
Cal-	QUARTERLY DIVIDENDS PAID B				Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2021	1.25	1.45	1.45	1.45	5.60
2022	1.45	1.65	1.65	1.65	6.40
2023	1.65	1.88	1.88	1.88	7.29
2024	1.88	2.10	2.10	2.10	8.18
2025					

through four operating segments: UnitedHealthcare (network-based health care benefits), OptumHealth, OptumInsight, and OptumRx (information and technology based health services, consulting, and Pharmacy Benefits Management). Acquired Amil Participacoes

After tumultuous а UnitedHealth Group stock sits right about where it did this time last year. Yes, there was a bit of a Trump bump in November, but December-period financials stalled that rally. This closed out a 12month window that started with a cyber attack and ended with the assassination of a top executive and the media frenzy that ensued. All the while, the company's medical cost ratio rose on heightened usage. Too, the general public is souring on what many are calling a broken healthcare system. Leadership has said the right things, and promised changes at the pharmacy benefits arm (an obvious target), but only time will tell if this will move the needle in terms of public opinion.

Jittery investors were looking for any bad signs in the 2024 fourth-quarter report, and they got some. The medical cost ratio spiked to 85.5%, after finishing 2023 at 83.2%. Patients are still opting in on surgeries/procedures put off during the COVID era. Government-backed Medicare plans for older adults have been very active. Separately, revenues from premiums at the UnitedHealth arm clocked in at

9.1% of common; BlackRock; officers & directors own 0.33% (4/24 Proxy). CEO: Andrew P. Witty. Incorporated: Minnesota. Address: 9900 Bren Road East, Minnetonka, Minnesota 55343, Telephone: 952-936-1300. Internet: www.unitedhealthgroup.com.

\$76.48 billion for the quarter, whereas the consensus was above \$78.0 billion. This led to an overall top-line miss in the vicinity of \$1 billion. We are viewing this as a short-term hiccup, though, and think revenues for 2025 will surpass the \$450 billion line, translating to earnings per share of around \$30.00.

The Amedisys deal window has been **extended.** The \$3.3 billion pact is being blocked by the Justice Department, as that entity argues UNH would have too much control in the home health and hospice space. The new agreement goes until the 10th day after a court decision or December 31, 2025, whichever is earlier. The Trump Administration is expected to be friendlier to consolidation, but regulators have been tough on this behemoth in the past, so time will tell. A failed merger would cost UNH as much as \$325 million in breakup fees

This top-quality selection (Safety: 1) looks to be about fairly valued in the current market. We recommend our subscribers await a better entry point before jumping in here.

Erik M. Manning February 28, 2025

(A) Diluted earnings. Excludes nonrecurring gains/(losses): '16, 80¢; '17, 65¢; '18, 68¢; '19, 78¢; '20, (85¢); '21, (94¢); '22, (\$1.01); '23, (\$1.26). May not sum due to rounding or

due mid-April. (B) Quarterly dividend initiated 6/10. Dividends

change in share count. Next earnings report | ber, and December. (C) Includes intangibles. In '24, \$118.9 billion, Company's Financial Strength Stock's Price Stability Price Growth Persistence **Earnings Predictability**

historically paid in late March, June, Septem- (D) In millions. © 2025 Value Line, Inc. All rights reserved. Factual material is obtained from sources believed to be reliable and is provided without warranties of any kind. THE PUBLISHER IS NOT RESPONSIBLE FOR ANY ERRORS OR OMISSIONS HEREIN. This publication is strictly for subscriber's own, non-commercial, internal use. No part of it may be reproduced, resold, stored or transmitted in any printed, electronic or other form, or used for generating or marketing any printed or electronic publication, service or product A+ 85

95